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Icodextrin-based dialysis solutions have been introduced toneal dialysis (CAPD). A total of 209 patients in the
to address an unmet clinical need in peritoneal dialysis, United Kingdom were enrolled and were treated for up
namely the difficulties inherent in ultrafiltration manage- to six months. The objectives of the study were to evalu-
ment during the long dwell [1–4]. These solutions take ate the efficacy of 7.5% icodextrin compared with low
advantage of the physiologic principle of colloid osmosis (1.5%) or high (4.25%) dextrose solutions when the dwell
and the high reflection coefficient of the glucose poly- time was 8 or 12 hours overnight. Approximately 40%
mers allows for ultrafiltration to proceed with dialysis of patients in the dextrose group used 4.25% dextrose
solutions iso-osmotic to plasma. While the efficacy and bags overnight prior to the study and the other patients
safety of icodextrin have been described in multiple pub- used 1.5% dextrose bags overnight prior to the study.
lications (abstracts; Douma et al, J Am Soc Nephrol 8: One hundred five patients were randomized in the low
282A, 1997; Wolfson et al, J Am Soc Nephrol 12:317A, dextrose arm of the study (55 patients, 1.5% dextrose;
2001; Wolfson et al, J Am Soc Nephrol 317A, 2001; Wood- 50 patients, 7.5% icodextrin). The mean age (approxi-
row et al, Perit Dial Int 14:140, 1998) [5–11], an integrated mately 57 years of age) was comparable between the
summary of the major controlled clinical trials is in order 1.5% dextrose and 7.5% icodextrin groups. Seventy-
as the use of this new class of osmotic agents widens three patients were randomized in the high dextrose arm
around the world. of the study (38 patients, 4.25% dextrose; 35 patients,
Evaluation of ultrafiltration during peritoneal dialysis 7.5% icodextrin). The mean age was 55 years in both
can be examined in two complementary approaches. A treatment groups.
quantitative approach examines the values of net ultra- Patients randomized to the icodextrin group received
filtration achieved under various therapeutic conditions. 7.5% icodextrin solution in place of their usual dextrose
A normative approach, however, is more clinically rele- solution for the nighttime dwell for six months. Patients
vant as it relates the ultrafiltration response to the thera- in the control group continued to receive their usual
peutic intent of the physician applying it. In the case of long dwell solution of either 1.5%, or 4.25% dextrose
ultrafiltration, the normative approach would examine solutions for the nighttime dwell. When dextrose concen-
the occurrence of negative net ultrafiltration with the tration usage for the long dwell was reviewed from the
various interventions, as this occurrence is contrary to baseline period, no patient reported using 2.5% dextrose
the therapeutic intent. Hence, negative net ultrafiltration in their usual prescription. Patients in both treatment
can be labeled as therapeutic failure and the relative groups continued their normal daytime exchanges using
occurrence of this condition can be used as a normative dextrose-based solutions. Overnight dialysis dwell times
measure to compare interventions. were controlled during six study weeks (weeks 3, 4, 12,
13, 20, and 21), in which all patients received their usual
8-hour (weeks 3, 12, and 20) or a standardized 12-hourTRIALS DESCRIPTION
(weeks 4, 13, and 21) overnight dwell.MIDAS Trial
The Multicenter Study of Icodextrin in Continuous North American CAPD Trial
Ambulatory Peritonal Dialysis (MIDAS Trial) was an This study was a prospective, randomized, double-
open, randomized, active controlled study comparing blind parallel group, active-controlled study of 175 con-
7.5% icodextrin with dextrose (1.5 to 4.25%) for the long/ tinuous ambulatory peritoneal dialysis (CAPD) patients
overnight dwell in patients on continuous ambulatory peri- enrolled in the United States and Canada. The objectives
of the study were to evaluate the efficacy and safety of
7.5% icodextrin compared with 2.5% dextrose peritonealKey words: ultrafiltration, dialysate, glucose polymers, CAPD, auto-
mated peritoneal dialysis, long dwell dialysis. dialysis solution. Patients were treated for one month.
Of the 175 patients enrolled in this study, 85 received di- 2002 by the International Society of Nephrology
S-46
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Fig. 1. MIDAS Study: Mean ultrafiltration (UF) in 1.5% dextrose-
treated patients () versus 7.5% icodextrin-treated continuous ambula-
Fig. 2. MIDAS Study: Mean UF in 1.5% dextrose-treated patients ()tory peritoneal dialysis (CAPD) patients () for the 8-hour dwell.
versus 7.5% icodextrin-treated CAPD patients () for the 12-hour dwell.
alysis treatment with 2.5% dextrose, and 90 patients re- In addition to comparisons of net ultrafiltration at dis-
ceived 7.5% icodextrin. Net UF for the long nighttime crete time periods, the mean change from baseline in net
dwell was measured at weeks 2 and 4. Overnight dialysis UF was evaluated. Analysis of covariance (ANCOVA)
dwell times in this study were 12  4 hours. revealed that the mean changes in UF were significantly
greater in the 7.5% icodextrin group compared with theEuropean APD Trial
1.5% dextrose group at weeks 3, 12, and 20 (P  0.001
This study was a prospective, randomized, open-label at all 3 visits).
parallel group, active-controlled study comparing the safety 12-hour dwell. Figure 2 illustrates the net UF of the
and efficacy of icodextrin 7.5% with 2.5% dextrose in pa- 12-hour nighttime dwell at baseline and weeks 4, 13, and
tients treated with automated peritoneal dialysis (APD). 21 for the 1.5% dextrose and 7.5% icodextrin treatment
A total of 39 patients were enrolled in this 16-week study groups. The mean net UF at baseline was comparable
(2 weeks of baseline evaluation, 12 weeks treatment, 2 between the 7.5% icodextrin group and the 1.5% dex-
weeks follow-up). Of the 39 patients enrolled in this trose group (61 mL vs. 76 mL, respectively; P  0.846).
study, 19 received 2.5% dextrose for the long daytime Mean net UF was increased in the 7.5% icodextrin group
dwell and 20 patients received 7.5% icodextrin. The pri- compared with the 1.5% dextrose group at weeks 4 (530
mary efficacy parameter for this study was net UF for vs. 73 mL), 13 (497 vs. 50 mL), and 21 (552 vs. 126 mL).
the long daytime dwell. Daytime dialysis dwell times in In addition to comparisons of net ultrafiltration at
this study were 14  2 hours. Primary efficacy variables discrete time periods, the mean change from baseline in
were measured at baseline, weeks 1, 6, and 12, and during net UF was evaluated. Analysis of covariance revealed
follow-up when only glucose-based dialysis solutions that the mean changes in UF were significantly higher
were used. in the 7.5% icodextrin group compared with the 1.5%
dextrose group at weeks 4, 13, and 21 (P  0.001 at all
3 visits).EFFECTS ON NET ULTRAFILTRATION IN CAPD
7.5% icodextrin versus 1.5% dextrose 7.5% icodextrin versus 2.5% dextrose
The 8-hour dwell. Figure 1 illustrates the net ultrafil- Figure 3 illustrates the net UF at the completion of
tration (UF) during the 8-hour nighttime dwell at base- the 12  4 hour dwell at baseline, week 2 and week 4
line and weeks 3, 12, and 20 for the 1.5% dextrose and for the 2.5% dextrose and 7.5% icodextrin treatment
7.5% icodextrin treatment groups. The mean net UF at groups. The mean net UF at baseline was comparable
baseline was comparable between the 7.5% icodextrin between the 7.5% icodextrin group and the 2.5% dex-
group and the 1.5% dextrose group (61 mL vs. 76 mL, trose group (262 vs. 329 mL; P  0.230). Mean net UF
respectively; P  0.846). Mean net UF was increased was increased in the 7.5% icodextrin group compared
in the 7.5% icodextrin group compared with the 1.5% with the 2.5% dextrose group at both the week 2 (578
dextrose group at week 3 (497 vs. 151 mL), week 12 (481 vs. 390 mL) and week 4 visits (606 vs. 380 mL).
In addition to comparisons of net ultrafiltration atvs. 142 mL), and week 20 (517 vs. 153 mL).
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Fig. 3. North American CAPD Trial: Mean UF in 2.5% dextrose-
Fig. 5. MIDAS Study: Mean UF in 4.25% dextrose-treated patientstreated patients () versus 7.5% icodextrin-treated patients () for
() versus 7.5% icodextrin–treated CAPD patients () for the 12-hourthe 12  4-hour dwell.
dwell.
(528 vs. 615 mL), week 12 (515 vs. 553 mL), and week
20 (462 vs. 465 mL).
In addition to comparisons of net ultrafiltration at
discrete time periods, the mean change from baseline in
net UF was evaluated. ANCOVA revealed that the mean
changes in net UF between the 7.5% icodextrin and the
2.5/4.25% dextrose treatment groups were significantly
different at week 3 (P  0.011), but not significantly
different at weeks 12 (P  0.246) and 20 (P  0.372).
12-hour dwell. Figure 5 illustrates the net UF at the
completion of the 12-hour nighttime dwell at baseline
and weeks 4, 13, and 21 for the 4.25% dextrose and
7.5% icodextrin treatment groups. The mean net UF at
baseline was comparable between the 7.5% icodextrin
group and the 4.25% dextrose group (711 vs. 614 mL;
P 0.232). Mean net UF was greater in the 7.5% icodex-Fig. 4. MIDAS Study: Mean UF in 4.5% dextrose-treated patients ()
versus 7.5% icodextrin-treated CAPD patients () for the 8-hour dwell. trin group compared with the 4.25% dextrose group at
week 4 (607 vs. 498 mL), week 13 (592 vs. 458 mL), and
week 21 (510 vs. 427 mL).
In addition to comparisons of net ultrafiltration atdiscrete time periods, the mean change from baseline in
discrete time periods, the mean change from baseline innet UF was evaluated. ACOVA revealed that the mean
net UF was evaluated. Although the net UF was greaterchanges in UF were significantly higher in the 7.5% ico-
in the 7.5% icodextrin group compared with the highdextrin group compared with the 2.5% dextrose group
dextrose group, ANCOVA revealed that the meanat both weeks 2 (P  0.008) and 4 (P  0.001).
changes in UF were not significantly different between
7.5% icodextrin versus 4.25% dextrose the two treatment groups at weeks 4 (P  0.405), 13
(P  0.400), and 21 (P  0.687).8-hour dwell. Figure 4 shows the net UF at the com-
pletion of the 8-hour nighttime dwell at baseline and
weeks 3, 12, and 20 for the 4.25% dextrose and 7.5% EFFECT ON THERAPEUTIC FAILURE IN CAPD
icodextrin treatment groups. The mean net UF at base-
7.5% icodextrin versus 1.5% dextroseline was comparable between the 7.5% icodextrin group
8-hour dwell. Figure 6 illustrates the percentage ofand the 4.25% dextrose group (711 vs. 614 mL; P 
patients with negative net UF at baseline and weeks 3,0.232). Mean net UF was comparable between the 7.5%
icodextrin group and the 4.25% dextrose group at week 3 12, and 21 in patients using either 1.5% dextrose or 7.5%
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Fig. 8. North American CAPD Trial: Percent of patients with negativeFig. 6. MIDAS Study: Percent of CAPD patients with negative net
net UF for the 12  4-hour dwell. Symbols are: () 2.5% dextrose,UF for the 8-hour dwell. Symbols are: () 1.5% dextrose, () 7.5%
() 7.5% icodextrin.icodextrin.
percentage of patients with negative net UF was signifi-
cantly reduced in the 7.5% icodextrin group compared
with the 1.5% dextrose group at weeks 4 (5 vs. 31%;
P 0.001), 13 (3 vs. 39%; P 0.001), and 21 (0 vs. 26%,
P  0.001).
7.5% icodextrin versus 2.5% dextrose
Figure 8 illustrates the percentage of patients with
negative net UF at baseline, and weeks 2 and 4 in 20 in
patients using either 2.5% dextrose or 7.5% icodextrin
for the 12  4-hour nighttime dwell. The percentage of
patients with negative net UF at baseline was compara-
ble between the 7.5% icodextrin group and the 2.5%
dextrose group (20 vs. 19%; P  0.844). The percentage
of patients with negative net UF was significantly re-
duced in the 7.5% icodextrin group compared with theFig. 7. MIDAS Study: Percent of CAPD patients with negative net
UF for the 12–hour dwell. Symbols are: () 1.5% dextrose, () 7.5% 2.5% dextrose group at weeks 2 (2 vs. 15%; P  0.004)
icodextrin. and 4 (0 vs. 13%; P  0.001).
7.5% icodextrin versus 4.25% dextrose
8-hour dwell. Figure 9 illustrates the percentage of pa-icodextrin for the 8-hour nighttime dwell. The percent-
age of patients with negative net UF at baseline was tients with negative net UF at baseline and weeks 3, 12,
and 20 in patients using either 4.25% dextrose or 7.5%comparable between the 7.5% icodextrin group and the
1.5% dextrose group (33 vs. 27%; P  0.652). The per- icodextrin for the 8-hour nighttime dwell. The percent-
age of patients with negative net UF at baseline was 3%centage of patients with negative net UF was significantly
reduced in the 7.5% icodextrin group compared with the in both the 7.5% icodextrin and the 4.25% dextrose
treatment groups. Although the percentage of patients1.5% dextrose group at weeks 3 (0 vs. 30%; P  0.001),
12 (0 vs. 25%; P 0.001), and 20 (0 vs. 29%, P 0.001). with negative net UF was lower in the 7.5% icodextrin
group than in the 4.25% dextrose group, the reduction12-hour dwell. Figure 7 illustrates the percentage of
patients with negative net UF at baseline and weeks 4, was not statistically significant. The percentages of pa-
tients with a negative net UF in the 7.5% icodextrin13, and 21 20 in patients using either 1.5% dextrose or
7.5% icodextrin for the 12-hour nighttime dwell. The group compared with the 4.25% dextrose group weeks 3,
12, and 20, respectively, were: 4 versus 7% (P  1.000),percentage of patients with negative net UF at baseline
was comparable between the 7.5% icodextrin group and 0 versus 7% (P  0.497), and 5 versus 13% (P  0.618).
12-hour dwell. Figure 10 illustrates the percentage ofthe 1.5% dextrose group (33 vs. 27%; P  0.652). The
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Fig. 9. MIDAS Study: Percent of CAPD patients with negative net
Fig. 11. European Automated Peritoneal Dialysis (APD) Trial: MeanUF for the 8-hour dwell. Symbols are: () 4.5% dextrose, () 7.5%
UF in 2.5% dextrose-treated patients () versus 7.5% icodextrin-icodextrin.
treated patients () for the 14  2-hour dwell.
EFFECTS ON NET ULTRAFILTRATION IN APD
Net UF from the long daytime dwell exchange in APD
was determined at the completion of the 14  2 hour
dwell at baseline, weeks 1, 6, and 12, and during follow
up for the 2.5% dextrose and 7.5% icodextrin treatment
groups (Fig. 11). Both treatment groups had a negative
net UF during the long dwell at baseline while receiving
2.5% dextrose. The mean net UF at baseline was compa-
rable between the 7.5% icodextrin group and the 2.5%
dextrose group (175 vs. 135 mL; P  0.697). Within
the first week the mean net UF was increased in the
7.5% icodextrin group to a positive net UF (323 vs.136
mL). Similar results were obtained at weeks 6 (292 vs.
115 mL) and 12 (206 vs. 165 mL).
Fig. 10. MIDAS Study: Percent of CAPD patients with negative net In addition to comparisons of net ultrafiltration at
UF for the 12-hour dwell. Symbols are: () 4.5% dextrose, () 7.5% discrete time periods, the mean change from baseline inicodextrin.
net UF was evaluated. ANCOVA revealed that the mean
changes in net UF were significantly higher in the 7.5%
icodextrin compared with the 2.5% dextrose groups at
patients with negative net UF at baseline and weeks 4, weeks 1, 6, and 12 (P  0.001 at all 3 visits).
13, and 21 in patients using either 4.25% dextrose or
7.5% icodextrin for the 12-hour nighttime dwell. The
EFFECT ON THERAPEUTIC FAILURE IN APDpercentage of patients with negative net UF at baseline
Figure 12 illustrates the percentage of patients withwas 3% in both the 7.5% icodextrin and the 4.25% dex-
negative net UF at baseline and weeks 1, 6, and 12 duringtrose groups. Although the percentage of patients with
the 14  2-hour long daytime dwell. The percentage ofnegative net UF was reduced in the 7.5% icodextrin
group compared with 4.25% dextrose group at weeks 4, patients with negative net UF at baseline was comparable
between the 7.5% icodextrin group and the 2.5% dex-13, and 21, this reduction was not statistically significant.
The percentages of patients with a negative net UF in trose group (75 vs. 74%; P  1.000). The percentage of
patients with negative net UF was significantly reducedthe 7.5% icodextrin group compared with the 4.25%
dextrose group at weeks 4; 13, and 21, respectively, were: in the 7.5% icodextrin group compared with the 2.5%
dextrose group at weeks 1 (15 vs. 68%; P  0.001), 60 versus 13% (P  0.113), 0 versus 14% (P  0.117),
and 0 versus 16% (P  0.114). (6 vs. 67%; P  0.001), and 12 (6 vs. 71%; P  0.001).
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Table 1. Incidence of skin rash
Dextrose Icodextrin
Group size Incidence Group size Incidence
N % N %
Overall 347 4.6 493 10.1
Age 65 years 95 6.3 123 8.1
Male 175 2.3 278 6.8
Female 172 7.0 215 14.4
Caucasian 257 4.3 360 10.0
Black 62 4.8 90 8.9
Diabetes mellitus 94 5.3 132 10.6
nificantly by gender with women having a higher inci-
dence rate than men (Table 1). Further, no association
was found between the development of the rash and theFig. 12. European APD Trial: Percent of patients with negative net
steady state blood levels of oligosaccharides.UF for the 14  2-hour dwell. Symbols are: () 2.5% dextrose; ()
7.5% icodextrin. The rash related to icodextrin usually occurred in the
early phase of therapy. This is reflected in the observed
declining incidence over time in the clinical studies: while
the overall rate was 10.1%, it declined to 4.7% in patientsADVERSE EVENTS
on treatment for more than 180 days, and to 2.6% in pa-
The adverse events profile of icodextrin-based solu- tients on treatment for more than one year. The rash
tions is similar to that of peritoneal dialysis solutions in was mild or moderate in the majority of patients (mild
general except for a few specific areas that warrant de- 46.4%, moderate 48.2%), and resolved with discontinua-
tailed description. Two such adverse events are dis- tion of icodextrin use without any sequelae (Baxter
cussed: the first, skin rash, because it is the most common Healthcare Corporation, data on file). The rash typically
treatment-related adverse event observed in clinical tri- involved the palms and soles and in a minority of patients
als, and the second, peritonitis, because it is has been was associated with mild peeling of the skin.
the subject of confusion in the literature [12].
Bacterial peritonitis
Skin rash A recent review has suggested that the incidence of
The development of a new skin rash is the most com- bacterial peritonitis may be increased in patients using
mon treatment-related side effect of the use of icodextrin icodextrin-based solution for the long dwell [12]. The
[abstracts; Prichard et al, Perit Dial Int 21(Suppl 2):S81, review examined the rates of peritonitis reported in the
2001; Russo et al, Perit Dial Int 20:145, 2000; Goldsmith initial trials of icodextrin, and while acknowledging the
et al, Perit Dial Int 20:125, 2000] [13–17]. Because skin differences at baseline between the two groups that may
disorders are common in patients on dialysis, it is impor- account for the observed differences, left the impression
tant to always contrast the incidence of this event with that the numerical tendencies of higher peritonitis rates
the background incidence observed in patients using ex- with icodextrin may be representative [12]. The review
clusively glucose-based dialysis solutions. Such a side- failed to mention that the apparent differences between
by-side comparison based on all clinical trials combined the two groups were not statistically significant. The re-
is shown in Table 1. The incidence rates listed in the Ta- view also failed to report the findings of Posthuma et al
ble reflect the occurrence of de novo skin rashes ob- that found no difference in the incidence of peritonitis
served during the course of the trials. Patients on icodex- between patients using dextrose and patients on icodex-
trin had a higher incidence of rash (10.1%) compared trin (1 per 17.6 months and 1 per 21.9 months, respec-
to patients on dextrose-based solutions for the long dwell tively) [9].
(4.6%; P  0.003). Because the occurrence of rash is We examined the incidence of peritonitis in the con-
recognized to be influenced by a variety of factors, sub- trolled clinical trials of icodextrin including the earlier
group analysis was performed to determine how these studies mentioned above. Peritonitis occurred in 25.4%
factors influence the incidence rate of rash (abstract; of 347 patients in the control group and 26.4% of 493
Russo, ibid). In both patients on dextrose-based solu- patients in the icodextrin group (Baxter Healthcare Cor-
tions for the long dwell and patients on icodextrin, the poration, data on file). The peritonitis led to withdrawal
incidence of rash appeared not to be influenced by age, from the studies in 4% of patients in the control group
and 3.7% of patients in the icodextrin group (Baxterrace, or the presence of diabetes, but to be affected sig-
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3. Krediet RT, van Westrhenen R, Zweers MM, Struijk DG: Clini-Healthcare Corporation, data on file). Hospitalization
cal advantages of new peritoneal dialysis solutions. Nephrol Dial
due to peritonitis, however, was lower in the icodextrin Transplant 17(Suppl 3):16–18, 2002
4. Mujais S, Nolph K, Gokal R, et al: Evaluation and management ofgroup (5.3%) than in the control group (8.6%, P 0.013;
ultrafiltration problems in peritoneal dialysis. International SocietyBaxter Healthcare Corporation, data on file). These re-
for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Man-sults show that the incidence of peritonitis in patients agement in Peritoneal Dialysis. Perit Dial Int 20(Suppl 4):S5–
using icodextrin is not different from that of patients S21, 2000
5. Gokal R, Mistry CD, Peers E: A United Kingdom multicenterusing dextrose for the long dwell.
study of icodextrin in continuous ambulatory peritoneal dialysis
(MIDAS). Perit Dial Int 14(Suppl 2):S22–S27, 1994
6. Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, et al: Peri-CONCLUSION toneal transport characteristics with glucose polymer based dialy-
sate. Kidney Int 50:979–986, 1996The efficacy data from the clinical trials provide evi-
7. Mistry CD, Gokal R, Peers E, MIDAS Study Group: A ran-dence that patients treated with icodextrin have an im- domized multicenter clinical trial comparing isosmolar icodextrin
proved UF profile compared with either the 1.5% or with hyperosmolar glucose solutions in CAPD. Kidney Int 46:496–
503, 19942.5% dextrose solutions, as it provides both significantly
8. Plum J, Gentile S, Verger C, et al: Efficacy and safety of agreater UF and also reduces the percentage of patients 7.5% icodextrin peritoneal dialysis solution in patients treated with
with negative net UF. In addition, it provides enhanced automated peritoneal dialysis. Am J Kidney Dis 39:862–871, 2002
9. Posthuma N, ter Wee PM, Donker AJM, et al: Assessment of thewaste solute clearance as compared to 1.5% and 2.5%
effectiveness, safety, and biocompatibility of icodextrin in automateddextrose solutions. The safety data from the clinical trials
peritoneal dialysis. Perit Dial Int 20(Suppl 2):S106–S113, 2000
provide evidence that icodextrin is a well-tolerated dialy- 10. Posthuma N, ter Wee PM, Verbrugh HA, et al: Icodextrin instead
of glucose during the daytime dwell in CCPD increases ultrafiltra-sate with an adverse event profile generally similar to
tion and 24-h dialysate creatinine clearance. Nephrol Dial Trans-dextrose dialysate. Dermatological adverse events (par-
plant 12:550–553, 1997
ticularly rash and exfoliative dermatitis) are more com- 11. Woodrow G, Oldroyd B, Stables G, et al: Effects of icodextrin in
mon in icodextrin-treated patients, but are usually mild automated peritoneal dialysis on blood pressure and bioelectrical
impedance analysis. Nephrol Dial Transplant 15:862–866, 2000or moderate in intensity, appear during the first three
12. Diaz-Buxo JA, Passlick-Deetjen J, Gotloib L: Potential hazardsweeks of therapy, and often resolve with discontinuation of polyglucose. ASAIO J 47:602–607, 2001
of icodextrin. 13. Divino Filho JC: Allergic reactions to icodextrin in patients with
renal failure. Lancet 355:1364–1365, 2000
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